PharmaTher Holdings Ltd. (PHRM.CN)
| Previous Close | 0.1750 |
| Open | 0.1700 |
| Bid | 0.1700 x N/A |
| Ask | 0.1800 x N/A |
| Day's Range | 0.1600 - 0.1950 |
| 52 Week Range | 0.0550 - 0.3550 |
| Volume | |
| Avg. Volume | 63,663 |
| Market Cap | 17.193M |
| Beta (5Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0530 |
| Earnings Date | Oct 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- GlobeNewswire
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
PharmaTher’s 5th FDA orphan drug designation for KETARX™ (ketamine) Phase 2 clinical study results to support proposed Phase 3 development of KETARX™ (ketamine) to treat Rett Syndrome for FDA approval via the 505(b)(2) regulatory pathway TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan
- Baystreet
Stocks in play: PharmaTher Inc
Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing ...
- GlobeNewswire
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in advancing specialty ketamine pharmaceuticals, today submitted its meeting package with the U.S. Food and Drug Administration (“FDA”) to discuss advancing KETARX™ (racemic ketamine) into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease (“LID-PD”). This Type C meeting allows the Company to discuss with the FDA its plans
